Perioperative bromocriptine adjuvant treatment for operable breast cancer.
Blood levels of prolactin are consistently raised in women who have undergone mastectomy for breast cancer, probably because of the stress of surgery. Since this increase in concentration of a known breast epithelial growth promoter might stimulate proliferation in micrometastatic cells shed at the time of surgery, a pilot study was conducted to try to abolish this effect. 38 patients with suspected operable breast cancer were given either bromocriptine (18) or placebo (20) tablets for 5 days preoperatively and thereafter for 3-10 days. Bromocriptine-treated patients showed significant reductions in prolactin levels and in S-phase fraction of tumour cells within the primary infiltrating carcinoma. There were no major side-effects. Perioperative bromocriptine may provide another approach to adjuvant therapy, possibly combined with endocrine or cytotoxic treatment for patients with axillary nodal metastases.
D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007432:Intraoperative Period; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control; D010865:Pilot Projects; D011388:Prolactin / Q000097:blood; D011897:Random Allocation
D004273:DNA, Neoplasm; D001971:Bromocriptine; D011388:Prolactin